FTXH - ETF AI Analysis
Top Page
First Trust Nasdaq Pharmaceuticals ETF (FTXH)
FTXH, the First Trust Nasdaq Pharmaceuticals ETF, earns a solid overall rating thanks to its heavy exposure to strong, established pharma leaders like Merck, Johnson & Johnson, Pfizer, and Eli Lilly, which benefit from robust financial performance, positive earnings outlooks, and well-developed drug pipelines. These strengths are partly offset by weaker names such as Viatris, where profitability and valuation challenges weigh on the fund. The main risk factor is the ETF’s concentration in the pharmaceutical sector, meaning its performance is closely tied to industry-specific trends, regulation, and drug development outcomes.
FTXH vs. SPDR S&P 500 ETF (SPY)
- AUM
- 1.18B
- Region
- North America
- Expense Ratio
- 0.60%
- Beta
- 0.45
- Issuer
- First Trust
- Inception Date
- Sep 20, 2016
- Dividend Yield
- 0.66%
- Asset Class
- Equity
- Index Tracked
- Nasdaq US Smart Pharmaceuticals Index
FTXH Summary
FTXH is the First Trust Nasdaq Pharmaceuticals ETF, which follows the Nasdaq US Smart Pharmaceuticals Index. It focuses on U.S. drugmakers and other health care companies working on new medicines and treatments. Well-known holdings include AbbVie and Eli Lilly, along with Pfizer and Johnson & Johnson. Someone might invest in FTXH to tap into the long-term growth potential of the pharmaceutical industry and to diversify within health care, instead of picking individual stocks. A key risk is that it is heavily concentrated in pharmaceutical companies, so its value can rise or fall sharply with changes in drug approvals, regulations, and health care trends.
How much will it cost me?
This ETF has an expense ratio of 0.60%, which means you’ll pay about $6 per year for every $1,000 you invest. That’s higher than the average low-cost index ETF because this fund uses a more specialized, smart-index approach to focus on pharmaceutical stocks.
What would affect this ETF?
FTXH could benefit if demand for new medicines stays strong, major U.S. drugmakers like AbbVie, Eli Lilly, and Pfizer successfully launch new treatments, and health care spending and supportive regulations continue to favor pharmaceutical innovation. On the negative side, tighter drug pricing rules, patent expirations, safety or approval setbacks, and broader economic or interest rate changes that make defensive health care stocks less attractive could weigh on this U.S.-focused pharmaceuticals ETF.
FTXH Top 10 Holdings
FTXH is essentially a who’s‑who of U.S. Big Pharma, with heavy exposure to giants like AbbVie, Eli Lilly, Pfizer, Johnson & Johnson, and Merck. Recent leaders such as Merck, Biogen, Amgen, and Viatris have been rising and help power the fund, while steadier names like J&J and Pfizer provide ballast with more measured gains. The portfolio is tightly focused on the pharmaceutical corner of health care, so performance is driven less by broad market swings and more by drug pipelines, patent news, and regulatory decisions in this single, U.S.-centric niche.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 LLY | Eli Lilly & Co | 8.22% | $97.54M | $1.33T | 67.86% | 72Outperform |
 ABBV | AbbVie | 7.72% | $91.54M | $521.11B | 29.22% | 66Neutral |
 PFE | Pfizer | 7.20% | $85.36M | $173.95B | 25.65% | 74Outperform |
 JNJ | Johnson & Johnson | 6.90% | $81.80M | $657.68B | 44.51% | 78Outperform |
 MRK | Merck & Company | 6.79% | $80.54M | $368.89B | 73.30% | 80Outperform |
 VTRS | Viatris | 3.87% | $45.88M | $21.86B | 83.74% | 60Neutral |
 BIIB | Biogen | 3.93% | $46.59M | $37.49B | 69.52% | 74Outperform |
 GILD | Gilead Sciences | 3.91% | $46.42M | $211.64B | 44.11% | 78Outperform |
 AMGN | Amgen | 3.64% | $43.14M | $251.94B | 59.59% | 77Outperform |
 UTHR | United Therapeutics | 3.49% | $41.45M | $25.68B | 32.01% | 79Outperform |
FTXH Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FTXH, the sentiment is Positive. The current price of 44.24 is above the 20-day moving average (MA) of 42.02, above the 50-day MA of 41.67, and above the 200-day MA of 37.12, indicating a bullish trend. The MACD of 0.69 indicates Negative momentum. The RSI at 70.67 is Negative, neither overbought nor oversold. The STOCH value of 84.20 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FTXH.
FTXH Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| FTXH | $44.24 | $46.00(3.98% Upside) | $1.18B | 0.60% | 72Outperform |
 IYH | $77.81 | $83.75(7.63% Upside) | $4.63B | 0.37% | 73Outperform |
 FHLC | $88.56 | $97.70(10.32% Upside) | $3.95B | 0.08% | 71Outperform |
 IHI | $54.59 | $62.59(14.65% Upside) | $3.73B | 0.37% | 74Outperform |
 FBT | $278.55 | $337.34(21.11% Upside) | $3.14B | 0.55% | 71Outperform |
 IHE | $107.61 | $126.62(17.66% Upside) | $1.60B | 0.37% | 70Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FTXH | First Trust Nasdaq Pharmaceuticals ETF | 44.24 | 14.50 | 48.74% | |
| IYH | iShares U.S. Healthcare ETF | 77.81 | 17.68 | 29.39% | |
| FHLC | Fidelity MSCI Health Care Index ETF | 88.56 | 19.89 | 28.96% | |
| IHI | iShares U.S. Medical Devices ETF | 54.59 | -5.85 | -9.69% | |
| FBT | First Trust NYSE Arca Biotechnology Index Fund | 278.55 | 86.33 | 44.91% | |
| IHE | iShares U.S. Pharmaceuticals ETF | 107.61 | 32.47 | 43.21% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.